Clin2
NCT07469293Worth exploringNot yet recruiting

Clot-busting drug for stroke from medium vessel blockage

Acute Ischemic Stroke

Treatments studied

Part of Brain & nervous system, Heart & circulation clinical trials.

This trial tests whether giving a clot-busting drug called tenecteplase directly into the blocked blood vessel in the brain can help people with a medium-sized vessel occlusion stroke. The drug may help restore blood flow and reduce disability, and it is given within 24 hours of symptom onset.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 3
Enrollment
488 people
Ages
18 years to 100 years
Study type
Interventional

Who can take part

  • You are 18 years or older.
  • You had a stroke caused by a blockage in a medium-sized blood vessel in the brain, and this was confirmed by imaging.
  • Your stroke symptoms started within the last 24 hours before the study begins.
  • You have a moderate or severe stroke, with a score of at least 5 on the NIHSS (a standard stroke severity scale).
  • Before this stroke, you were fully independent (able to do daily tasks without help).
  • You have not received clot-busting drugs or had a mechanical clot removal procedure for this stroke, and you do not have any bleeding in the brain.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07302854Recruiting· Phase 2/Phase 3
Clot-busting medicine for medium vessel strokes

This trial tests a new clot-busting medicine called tenecteplase, given directly into the blood vessel in the brain, to treat strokes caused by a blockage in a medium-sized artery. The goal is to see if it can help restore blood flow and reduce disability, especially for patients who can be treated within 24 hours of stroke onset.

Wuhan, Hubei
NCT06559436Recruiting
Extending window for clot-busting drug in medium vessel stroke

This trial tests a clot-dissolving drug called tenecteplase given 4.5 to 24 hours after a stroke caused by a blockage in a medium-sized brain artery. It aims to see if waiting longer than usual still helps reduce disability.

Hefei, Anhui
NCT07137832Recruiting· Phase 3
Testing clot-busting drug during stroke treatment for medium vessel blockages

This trial tests whether giving a clot-dissolving medication directly into the brain's blood vessels during a standard procedure (mechanical thrombectomy) can improve outcomes for people with a stroke caused by a blockage in a medium-sized artery. It may be an option for patients who arrive at the hospital within 24 hours of symptom onset and have enough salvageable brain tissue.

Guangzhou, Guangdong
NCT07168278Not yet recruiting· Phase 3
Clot-busting drug vs standard care for late large-vessel stroke

This trial tests whether a clot-dissolving drug called tenecteplase can improve recovery for people who had a large-vessel ischemic stroke 4.5 to 24 hours earlier and can’t have a mechanical clot removal procedure in time. If you join, you’ll get either tenecteplase or standard medical care, and the study will track your recovery and safety.

Hefei, Anhui
NCT07621796Not yet recruiting· Phase 3
Clot-buster treatment for stroke patients on blood thinners

This trial tests whether a stronger clot-busting drug (tenecteplase) is safe and works for people who have had a stroke while taking a common blood thinner. If you qualify, you may get this treatment within a few hours of your stroke to help improve recovery.

Neptune City, New Jersey
NCT06781385Enrolling by invitation· Phase 2
Tenecteplase after clot removal for severe stroke

This trial tests if giving a clot-busting drug (tenecteplase) directly into the brain artery after a successful clot-removal procedure can improve outcomes for people with a major stroke. It is for patients who had a large vessel blockage and received endovascular thrombectomy within 24 hours of symptoms starting.

Charlotte, North Carolina

Hear when a new Acute Ischemic Stroke trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.